{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025912","form_type":"8-K","ticker":"PYXS","cik":"0001782223","company_name":"Pyxis Oncology, Inc.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.095555+00:00","generated_at":"2026-06-21T11:03:10.213983+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA clears Pyxis Oncology INDs for PYX-201 ADC and PYX-106 immunotherapy","bullets":["FDA cleared IND for PYX-201, an ADC targeting tumor microenvironment for breast, head/neck, lung, thyroid cancers.","FDA cleared IND for PYX-106, an immunotherapy targeting Siglec-15 for bladder, cholangiocarcinoma, colorectal, kidney cancers.","Phase 1 trials planned to start in early 2023; cash runway extended into first half 2025.","Pyxis Oncology transitions to clinical-stage company with veteran leadership team."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025912","json":"https://secwatch.observer/filing/0000950170-22-025912.json","markdown":"https://secwatch.observer/filing/0000950170-22-025912.md","text":"https://secwatch.observer/filing/0000950170-22-025912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/0000950170-22-025912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1782223/000095017022025912/pyxs-20221201.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:03:10.213983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}